Study to Assess the Safety and Tolerability of the Tor Kinase Inhibitor AZD8055

AstraZeneca

Status and phase: Completed; Phase 1

Conditions: Cancer; Solid Tumors; Advanced Solid Malignancies

Treatments: Drug: AZD8055

Study type: Interventional

Funder types: Industry

Identifiers

NCT00973076

D1600C00003

Details and patient eligibility

About

The primary objective is to assess the safety and tolerability of AZD8055 in Japanese patients with advanced solid tumours.

Enrollment: 19 patients

Sex: All

Ages: 20+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Japanese patients with advanced solid tumors for which suitable effective standard treatment does not exist or is no longer effective
• Relatively good overall health other than cancer

Exclusion criteria

• Poor bone marrow function (not producing enough blood cells)
• Poor liver or kidney function
• Serious concomitant illness

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

19 participants in 1 patient group

AZD8055

Experimental group

Description:

AZD8055 will be administered orally

Treatment:

Drug: AZD8055